Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.

Journal of cancer research and clinical oncology - 9 May 2026

Bohne Ann-Sophie, Heber Marilena, Axt Franziska, von Bubnoff Nikolas, Kähler Katharina

Abstract excerpt

BACKGROUND: Risk stratification to guide adjuvant treatment in early stages of melanoma becomes increasingly important. This study investigated circulating tumor (ct)DNA in early melanoma stages to predict disease progression in real-world settings in German melanoma patients. METHODS: In this retrospective, single-center study, 61 patients with melanoma stages I-III with known disease-progression following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Melanoma

Share to Membrane Proteins

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42104999
DOI: 10.1007/s00432-026-06478-w
PMCID: PMC13168401

Genes

BRAF
NRAS
TERT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.PMID 42104999Read ↗

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.Semantic proximity Read ↗

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.Semantic proximity Read ↗

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.Semantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.Semantic proximity Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.